Ovarian Cancer

Kevin Elias, MD, discusses efficacy data from the PRIMA and NOVA trials evaluating niraparib as maintenance therapy in ovarian cancer.

Sarah Lynam, MD, discusses the clinical applicability of mirvetuximab soravtansine and trastuzumab deruxtecan in recurrent ovarian cancer.

Experts reflect on pivotal data, emerging agents, and notable advancements in gynecologic cancer spotlighted during the 2025 ESMO Congress.

Vanda Salutari, MD, discusses the rationale for examining relacorilant plus nab-paclitaxel in PARP inhibitor–treated platinum-resistant ovarian cancer.

Sarah Lynam, MD, details key efficacy data from the phase 2 DESTINY-PanTumor02 trial, evaluating trastuzumab deruxtecan in HER2-expressing solid tumors.

Raludotatug deruxtecan demonstrates antitumor activity and manageable safety in platinum-resistant ovarian cancer.

Chemotherapy plus durvalumab, bevacizumab, and olaparib did not significantly prolong OS in non-tBRCA-mutated ovarian cancer.

The addition of relacorilant to nab-paclitaxel produced a PFS benefit vs nab-paclitaxel alone in PROC with a history of PARP inhibitor exposure.

NAPISTAR1-01 showed enduring benefit with TUB-040 in patients with platinum-resistant high-grade serous ovarian cancer.

Pembrolizumab and paclitaxel with or without bevacizumab led to PFS and OS benefits vs placebo in place of pembrolizumab in recurrent, PD-L1–positive PROC.

Kevin Elias, MD, discusses the role of olaparib maintenance therapy for patients with BRCA1 and BRCA2-mutated ovarian cancer.

Pembrolizumab plus chemotherapy with or without bevacizumab improved overall survival in platinum-resistant ovarian cancer.

Sarah Lynam, MD, highlights the importance of folate receptor–alpha expression testing to inform treatment decision-making in patients with ovarian cancer.

The approval of relacorilant for use in patients with platinum-resistant ovarian cancer is sought from the European Medicines Agency.

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

Kevin Elias, MD, discusses the role of olaparib in the management of ovarian cancer.

Kevin Elias, MD, discusses the SOLO-1 and SOLO-2 trials, which evaluated olaparib in newly diagnosed and relapsed BRCA-mutated ovarian cancer.

See poll results highlighting the top gynecologic oncology abstracts and subtypes to watch at the 2025 ESMO Congress.

Sarah Lynam, MD, discusses the significance and implications of mirvetuximab soravtansine for the treatment of patients with ovarian cancer.

CDK4/6 inhibition with palbociclib demonstrated encouraging efficacy in patients with low-grade serous ovarian cancer.

Vote on the top abstracts and topics to watch in gynecologic and gastrointestinal oncology during the 2025 ESMO Congress.

Experts in the gynecologic cancer landscape highlight their most anticipated presentations ahead of the 2025 ESMO Congress.

Stenoparib monotherapy generated long-term clinical benefit in patients with platinum-resistant and -refractory advanced ovarian cancer.

A United Kingdom Conformity Assessed marking was granted to the Avantect Multi-Cancer Detection Test and Avantect Ovarian Cancer Test.

The top 5 OncLive TV videos of the week cover insights in lung cancer, multiple myeloma, and ovarian cancer.